Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DSNKY Daiichi Sankyo	$24.27 +0.7%	$24.27	$20.92 ▼ $35.88	$45.98B	N/A	253,783 shs	156,672 shs
ONC BeOne Medicines	$327.20 -1.5%	$302.05	$170.99 ▼ $351.27	$35.86B	0.21	427,960 shs	316,556 shs
RCDTF Recordati Industria Chimica E Farmaceutica	$65.44	$65.44	$49.00 ▼ $65.44	$13.50B	0.17	1 shs	N/A
TAK Takeda Pharmaceutical	$15.13 +0.5%	$14.81	$12.80 ▼ $15.69	$48.14B	0.22	2.61 million shs	1.99 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DSNKY Daiichi Sankyo	+1.05%	-4.22%	-3.98%	+1.09%	-33.73%
ONC BeOne Medicines	+2.44%	-4.09%	+3.39%	+30.77%	+33,226,999,900.00%
RCDTF Recordati Industria Chimica E Farmaceutica	0.00%	0.00%	0.00%	0.00%	+25.24%
TAK Takeda Pharmaceutical	-0.20%	-1.21%	+0.60%	+1.28%	+2.59%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DSNKY Daiichi Sankyo	$24.27 +0.7%	$24.27	$20.92 ▼ $35.88	$45.98B	N/A	253,783 shs	156,672 shs
ONC BeOne Medicines	$327.20 -1.5%	$302.05	$170.99 ▼ $351.27	$35.86B	0.21	427,960 shs	316,556 shs
RCDTF Recordati Industria Chimica E Farmaceutica	$65.44	$65.44	$49.00 ▼ $65.44	$13.50B	0.17	1 shs	N/A
TAK Takeda Pharmaceutical	$15.13 +0.5%	$14.81	$12.80 ▼ $15.69	$48.14B	0.22	2.61 million shs	1.99 million shs

A Guide To High-Short-Interest Stocks

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DSNKY Daiichi Sankyo	+1.05%	-4.22%	-3.98%	+1.09%	-33.73%
ONC BeOne Medicines	+2.44%	-4.09%	+3.39%	+30.77%	+33,226,999,900.00%
RCDTF Recordati Industria Chimica E Farmaceutica	0.00%	0.00%	0.00%	0.00%	+25.24%
TAK Takeda Pharmaceutical	-0.20%	-1.21%	+0.60%	+1.28%	+2.59%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DSNKY Daiichi Sankyo	4.00	Strong Buy	N/A	N/A
ONC BeOne Medicines	3.00	Buy	$330.89	1.13% Upside
RCDTF Recordati Industria Chimica E Farmaceutica	2.33	Hold	N/A	N/A
TAK Takeda Pharmaceutical	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest RCDTF, TAK, DSNKY, and ONC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	TAK Takeda Pharmaceutical	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/11/2025	RCDTF Recordati Industria Chimica E Farmaceutica	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/7/2025	ONC BeOne Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$349.00 ➝ $364.00
8/7/2025	ONC BeOne Medicines	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$350.00 ➝ $365.00
7/17/2025	ONC BeOne Medicines	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$321.00 ➝ $345.00
7/16/2025	ONC BeOne Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$311.00 ➝ $349.00
6/27/2025	ONC BeOne Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$313.00 ➝ $330.00
6/27/2025	ONC BeOne Medicines	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$317.00 ➝ $321.00
6/27/2025	ONC BeOne Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$311.00

(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DSNKY Daiichi Sankyo	$12.39B	3.71	$1.28 per share	19.01	$5.61 per share	4.33
ONC BeOne Medicines	$4.56B	7.86	N/A	N/A	$34.10 per share	9.60
RCDTF Recordati Industria Chimica E Farmaceutica	$2.53B	5.33	N/A	N/A	N/A	∞
TAK Takeda Pharmaceutical	$4.48T	0.01	$3.19 per share	4.75	$14.39 per share	1.05

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DSNKY Daiichi Sankyo	$1.95B	$1.03	23.56	22.27	1.17	15.65%	17.92%	8.61%	10/30/2025 (Estimated)
ONC BeOne Medicines	-$644.79M	-$1.73	N/A	460.85	N/A	-3.89%	-1.22%	-0.72%	N/A
RCDTF Recordati Industria Chimica E Farmaceutica	$450.70M	$2.00	32.72	∞	N/A	N/A	N/A	N/A	11/11/2025 (Estimated)
TAK Takeda Pharmaceutical	$712.33M	$0.30	50.43	9.17	N/A	3.20%	10.50%	5.10%	10/30/2025 (Estimated)

Latest RCDTF, TAK, DSNKY, and ONC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/6/2025	Q2 2025	ONC BeOne Medicines	$0.48	$0.84	+$0.36	$0.84	$1.24 billion	$1.32 billion
7/30/2025	Q1 2026	TAK Takeda Pharmaceutical	$0.47	$0.52	+$0.05	$0.27	$7.96 billion	$7.45 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DSNKY Daiichi Sankyo	$0.28	1.15%	N/A	27.18%	N/A
ONC BeOne Medicines	N/A	N/A	N/A	N/A	N/A
RCDTF Recordati Industria Chimica E Farmaceutica	N/A	N/A	N/A	N/A	N/A
TAK Takeda Pharmaceutical	$0.55	3.64%	N/A	183.33%	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DSNKY Daiichi Sankyo	0.06	2.53	1.85
ONC BeOne Medicines	0.04	1.95	1.72
RCDTF Recordati Industria Chimica E Farmaceutica	1.04	1.59	1.09
TAK Takeda Pharmaceutical	0.60	1.16	0.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DSNKY Daiichi Sankyo	N/A
ONC BeOne Medicines	48.55%
RCDTF Recordati Industria Chimica E Farmaceutica	N/A
TAK Takeda Pharmaceutical	9.17%

Insider Ownership

Company	Insider Ownership
DSNKY Daiichi Sankyo	N/A
ONC BeOne Medicines	6.62%
RCDTF Recordati Industria Chimica E Farmaceutica	N/A
TAK Takeda Pharmaceutical	0.04%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DSNKY Daiichi Sankyo	17,435	1.89 billion	N/A	Not Optionable
ONC BeOne Medicines	11,000	109.60 million	102.34 million	N/A
RCDTF Recordati Industria Chimica E Farmaceutica	4,583	206.30 million	N/A	Not Optionable
TAK Takeda Pharmaceutical	47,455	3.18 billion	3.18 billion	Optionable

RCDTF, TAK, DSNKY, and ONC Headlines

Recent News About These Companies

Takeda Flat on Hookup with VELA

September 16 at 11:09 AM | baystreet.ca

‘As close as one could get to living a near-normal life’: Experimental narcolepsy drugs bring hope to patients

September 16 at 11:09 AM | bostonglobe.comB

Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025

September 15 at 11:30 AM | finance.yahoo.com

Baird Financial Group Inc. Invests $276,000 in Takeda Pharmaceutical Co. $TAK

September 14 at 3:03 AM | marketbeat.com

Takeda poaches top Lilly exec; Maze soars on early PKU drug data

September 12, 2025 | biopharmadive.comB

Antibody Drug Conjugates Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes | Bristol Myers Squibb, GSK, MBrace therapeutics, Oxford Biotherapeutics ...

September 11, 2025 | theglobeandmail.com

Takeda Appoints Rhonda Pacheco President of the U.S. Business Unit

September 11, 2025 | pharmiweb.comP

Takeda Pharmaceutical (NYSE:TAK) Sets New 1-Year High - Should You Buy?

September 10, 2025 | marketbeat.com

CVS Sues Takeda, Bora Units Claiming Collusion on Reflux Drug

September 9, 2025 | news.bloomberglaw.comN

Nikkei ends lower on yen strength, profit-taking after crossing 44,000

September 9, 2025 | msn.com

Japan's Nikkei rises to 44,000 for first time on trade, spending optimism

September 9, 2025 | msn.com

Assessing Takeda Stock After Recent 6% Jump and New FDA Approval for HyQvia Expansion

September 9, 2025 | finance.yahoo.com

Takeda nears first therapy for root cause of narcolepsy

September 9, 2025 | japantimes.co.jpJ

Promising Phase 3 Results for Takeda’s Oveporexton Boost Buy Rating

September 9, 2025 | tipranks.com

Takeda Pharmaceutical Company Limited (TAK) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

September 9, 2025 | seekingalpha.com

Takeda Pharmaceutical Company Limited (TAK) Oveporexton (TAK-861) Investor Call On Phase 3 Narcolepsy Type 1 Data Presented At World Sleep 2025 (Transcript)

September 8, 2025 | seekingalpha.com

Takeda Pharmaceutical Company Limited (TAK) Special Call - Slideshow

September 8, 2025 | seekingalpha.com

Takeda Nears First Therapy for Narcolepsy’s Root Cause

September 8, 2025 | bloomberg.com

Nomura Holdings Inc. Invests $338,000 in Takeda Pharmaceutical Co. $TAK

September 8, 2025 | marketbeat.com

Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025

September 8, 2025 | businesswire.com

Adage Capital Partners GP L.L.C. Invests $51.05 Million in Takeda Pharmaceutical Co. $TAK

September 6, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RCDTF, TAK, DSNKY, and ONC Company Descriptions

Daiichi Sankyo OTCMKTS:DSNKY

$24.27 +0.16 (+0.66%)

As of 03:59 PM Eastern

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.

BeOne Medicines NASDAQ:ONC

$327.20 -5.07 (-1.53%)

As of 04:00 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Recordati Industria Chimica E Farmaceutica OTCMKTS:RCDTF

$65.44 0.00 (0.00%)

As of 09/15/2025

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.

Takeda Pharmaceutical NYSE:TAK

$15.13 +0.07 (+0.46%)

Closing price 03:59 PM Eastern

Extended Trading

$15.12 -0.01 (-0.07%)

As of 04:10 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RCDTF, TAK, DSNKY, and ONC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RCDTF, TAK, DSNKY, and ONC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RCDTF, TAK, DSNKY, and ONC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RCDTF, TAK, DSNKY, and ONC Company Descriptions

Daiichi Sankyo OTCMKTS:DSNKY

BeOne Medicines NASDAQ:ONC

Recordati Industria Chimica E Farmaceutica OTCMKTS:RCDTF

Takeda Pharmaceutical NYSE:TAK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RCDTF, TAK, DSNKY, and ONC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RCDTF, TAK, DSNKY, and ONC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RCDTF, TAK, DSNKY, and ONC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RCDTF, TAK, DSNKY, and ONC Company Descriptions

Daiichi Sankyo OTCMKTS:DSNKY

BeOne Medicines NASDAQ:ONC

Recordati Industria Chimica E Farmaceutica OTCMKTS:RCDTF

Takeda Pharmaceutical NYSE:TAK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools